X0508 4 2024-01-03 false 0001560241 G1 Therapeutics, Inc. GTHX 0001706853 Malik Rajesh 700 PARK OFFICES DRIVE, SUITE 200 RESEARCH TRIANGLE PARK NC 27709 false true false false Chief Medical Officer false Common Stock 2024-01-03 4 A false 37300.00 0.00 A 173678.00 D Common Stock 2024-01-03 4 S false 758.00 3.1189 D 172920.00 D Common Stock 2024-01-03 4 S false 2261.00 3.1189 D 170659.00 D Common Stock 2024-01-04 4 S false 721.00 2.9423 D 169938.00 D Stock Options (Right to Buy) 2.97 2024-01-03 4 A false 74500.00 0.00 A 2034-01-03 Common Stock 74500.00 74500.00 D Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2025 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date. The shares underlying this option vest as to 25% of the shares on January 3, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Each RSU represents a contingent right to receive one share of Issuer common stock. Represents (i) 71,853 shares of common stock; (ii) 4,125 RSUs from award granted on January 4, 2021; (iii) 7,500 RSUs from award granted on January 3, 2022; (iv) 17,900 RSUs from award granted on January 3, 2023; (v) 35,000 RSUs from award granted on May 10, 2023; and (vi) 37,300 RSUs from award granted on January 3, 2024. The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person. The price represents the weighted average price with a low of $3.08 and a high of $3.16. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Represents (i) 72,595 shares of common stock; (ii) 4,125 RSUs from award granted on January 4, 2021; (iii) 6,000 RSUs from award granted on January 3, 2022; (iv) 17,900 RSUs from award granted on January 3, 2023; (v) 35,000 RSUs from award granted on May 10, 2023; and (vi) 37,300 RSUs from award granted on January 3, 2024. Represents (i) 74,809 shares of common stock; (ii) 4,125 RSUs from award granted on January 4, 2021; (iii) 6,000 RSUs from award granted on January 3, 2022; (iv) 13,425 RSUs from award granted on January 3, 2023; (v) 35,000 RSUs from award granted on May 10, 2023; and (vi) 37,300 RSUs from award granted on January 3, 2024. The price represents the weighted average price with a low of $2.89 and a high of $3.00. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Represents (i) 75,463 shares of common stock; (ii) 2,750 RSUs from award granted on January 4, 2021; (iii) 6,000 RSUs from award granted on January 3, 2022; (iii) 13,425 RSUs from award granted on January 3, 2023; (iv) 35,000 RSUs from award granted on May 10, 2023; and (v) 37,300 RSUs from award granted on January 3, 2024. /s / Monica Roberts Thomas, attorney-in-fact 2024-01-05